Case report: Exploring teduglutide as a therapeutic option for refractory microscopic colitis: insights and implications.

Front Med (Lausanne)

Department of Medicine, Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States.

Published: August 2023

Microscopic colitis is a chronic inflammatory condition of the colon characterized by chronic watery diarrhea, generally with endoscopically normal or nonspecific findings, and can be diagnosed by histopathological examination of colon mucosal biopsies. Some patients experience severe symptoms that do not respond to conventional medical treatment. A glucagon-like peptide-2 (GLP-2) analog, teduglutide, is used in patients with short bowel syndrome (SBS) dependent on parenteral support. In this case report, we describe a patient with microscopic colitis who demonstrated significant symptom improvement following teduglutide treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462905PMC
http://dx.doi.org/10.3389/fmed.2023.1231565DOI Listing

Publication Analysis

Top Keywords

microscopic colitis
12
case report
8
report exploring
4
exploring teduglutide
4
teduglutide therapeutic
4
therapeutic option
4
option refractory
4
refractory microscopic
4
colitis insights
4
insights implications
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!